Fermer le menu


Member of Lyonbiopole


Covalab is a privately-owned company specialized in the engineering of the antibodies using proprietary technologies adapted for the design of therapeutic antibodies. In addition Covalab as a CRO provides Universities, Research Institutes and Companies with a large range of services in immunology (DNA immunisation, Chemirisation, Humanisation, Directed mutations, nanobodies). Since 20 years Covalab supply large panel of unique and proprietary antibodies through it's e-commerce plateforme and distributors. The Covalab service and product platforms represent but the tip of the scientific and technical iceberg which the Covalab team has put together. Indeed, the scientists at Covalab hold more than 25 years of experience in the chemical modification of antigens and antibodies destined for diagnostic and therapeutic purposes. Amongst its achievements, Covalab has performed the production of antibodies directed against new tumour markers, antibodies as vectors (Immunoconjugate or ADC) in cancerology, antibodies reacting specifically with neo-epitopes, PTMs, mutations as well as many other challenging antigens, contributing to the filing of 6 patent applications. 


Strategic application domain: Human Medicine

Application market: Immune, AutoIm & Inflam. diseases, Oncology, Others

Type of activity: CMO - Production - Bioproduction, CRO - Tools - R&D platform, Therapeutics, Pharma or Biotech

Technologies: Antibodies - Protein - Peptide, Drug delivery device & Technologies, Immunotherapy

Created on july 1st, 1995 - 19 employees






Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.